Chlorthalidone

Mechanism

Pharmacological Group

Thiazide-like diuretic, derived from phthalimide (chemically different but functionally identical to thiazides).

Mechanism of Action

It reversibly and potently blocks the sodium and chloride symporter NCC in the Distal Convoluted Tubule. Additionally, it has a weak but constant inhibitory action on carbonic anhydrase. Its high binding to erythrocyte carbonic anhydrase acts as a systemic reservoir for slow release of the drug, which explains its extremely long elimination life and stable antihypertensive action.

Pharmacokinetics

Key Pharmacokinetics

• Bioavailability: 65%.
• Protein binding: Very high (~75% bound to albumin and massively accumulated in erythrocytes due to its binding with carbonic anhydrase).
• Elimination: Renal excretion of 50-70% of the unchanged drug.
• Half-life: 40 to 60 hours. Its duration of action extends up to 72 hours.

Indicators and dose

Clinical Indications

• Essential arterial hypertension: Preferred by international guidelines (such as those of the ACC/AHA) over hydrochlorothiazide due to its superiority for 24-hour blood pressure control and its accumulated evidence in the reduction of cardiovascular events (ALLHAT study).
• Mild to moderate cardiogenic or renal edema.

Dosage and Settings

• Hypertension: 12.5 mg to 25 mg orally once a day. Maximum recommended doses in hypertension up to 50 mg/day (rarely required).
• Edema: 50 mg to 100 mg daily or every other day.
• Renal adjustment: Ineffective in CrCl < 30 mL/min. In this population, the use of metolazone or loop diuretics should be preferred.

Security

Contraindications

Severe anuria; terminal renal failure with basal filtration inability; refractory hypokalemia; acute gout.

Adverse Effects (ADR)

• Very common: Hypokalemia (frequently requires oral potassium supplementation), clinically manifest hyperuricemia.
• Common: Glucose intolerance, cramps, hyponatremia, metabolic alkalosis, morning fatigue.

Interactions

Increases serum lithium levels by proximal reabsorption. Increases susceptibility to arrhythmias due to digoxin.

Pregnancy and Breastfeeding

Category B. Not recommended due to the risk of placental hypoperfusion. It is excreted in human milk; It is preferred to suspend breastfeeding or avoid the use of the drug.

Clinical

HCTZ vs Chlorthalidone in Clinical Practice

Although hydrochlorothiazide is more commonly prescribed due to its presence in multiple fixed-dose combinations, chlorthalidone is substantially more potent and effective. Its half-life of 40-60 hours ensures optimal blood pressure control, especially during the critical morning period (when most heart attacks and strokes occur), where the effect of HCTZ (half-life of 6-15h) has usually disappeared. However, this high potency carries a significantly increased risk of hypokalemia and hyponatremia, requiring more frequent monitoring of serum electrolytes during the initiation of treatment.